- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04813640
Eye Length Signal With Myopia Control
A Prospective, Randomised, Dispensing Clinical Trial to Compare the Visual Performance, Wearability and Ocular Response of Myopia Control, Novel Myopia Control and Single Vision Spectacle Lenses
Study Overview
Detailed Description
To date, the strategies used to control or slow the progression of myopia are optical and pharmaceutical methods. Among spectacles, bifocal spectacles with and without prism, progressive addition lenses, spectacles altering peripheral hyperopic defocus, spectacles imposing myopic defocus both centrally and peripherally and spectacles with multiple defocus segments that imposes myopic defocus in front, midperiphery and periphery of the retina (defocus incorporating multiple segments or DIMS) are used to reduce the progression[2-6]. Of these, spectacles designed to alter peripheral defocus demonstrated a small treatment effect in reducing myopia progression[6, 7]. Bifocal and progressive addition spectacles demonstrated variable treatment effect in reducing progression of myopia. Among contact lenses, multifocal contact lenses altering peripheral defocus, extended depth of focus contact lenses altering higher order aberrations in order to degrade the retinal image behind the retina have shown promising results in slowing myopia progression along with orthokeratology treatment[8-12]. Among these, orthokeratology and multifocal soft contact lenses (centre distance multifocal contact lenses) showed promising results in slowing myopia progression[9, 12].
Pharmaceutical interventions include Atropine, Pirenzepine, 7-Methylxanthine and Timolol[13].Atropine is the most widely used, with higher concentrations more effective. Atropine 1% concentration demonstrated 60 to 80% reduction in progression of myopia. However, ocular side effects such as blurred vision, photophobia etc associated with atropine makes it a less appealing option. Among the various treatment approaches, spectacles pose the least or minimal side effects compared to contact lenses, orthokeratology or pharmaceutical strategies. Therefore, this study aims to determine the effect of novel myopia control prototype spectacle design on wearability and physiological ocular response among myopic children aged 7 to 14 years.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Minh Huy Tran, M.D., Msc.
- Phone Number: (+84) 907 110 892
- Email: huy.tran@haiyeneyecare.com
Study Contact Backup
- Name: Padmaja Sankaridurg, BOpt, PhD
- Phone Number: 612 93857485
- Email: p.sankaridurg@bhvi.org
Study Locations
-
-
-
Ho Chi Minh City, Vietnam
- Recruiting
- Hai Yen Eye Care Center
-
Contact:
- Minh Huy Tran, MD, MSc
- Phone Number: (+84) 907110892
- Email: huy.Tran@haiyeneyecare.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- be aged between 7 to 14 completed years (7 and 14 years inclusive), irrespective of gender.
- have cycloplegic autorefraction spherical component -0.50 D to - 4.50D, cylinder no more than -1.50D
- be accompanied by parents/guardians who can read and comprehend Vietnamese and give informed consent as demonstrated by signing a record of informed consent.
- be willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
- have ocular health findings considered to be "normal".
- be correctable to at least 6/9.5 (20/30) or better in each eye with spectacles.
- be willing to wear the spectacles provided by the investigators for all waking hours;
Exclusion Criteria:
- A known allergy to, or a history of intolerance to tropicamide or topical anaesthetics;
- Strabismus and/or amblyopia;
- Had previous eye surgery (including strabismus surgery);
- Any ocular, systemic or other condition or disease with possible associations with myopia or affecting refractive development e.g. Marfan syndrome, retinopathy of prematurity, diabetes;
- Had any ocular injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids;
- Worn bifocals or progressive addition spectacles;
- Worn orthokeratology or bifocal contact lenses;
- Current orthoptic treatment or vision training;
- Any anatomical, skin or other condition that would impact on the wearing of spectacles;
- Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial.
- Concurrently enrolled in another clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Single Vision Spectacles
Commercially available conventional single vision spectacles
|
Novel spectacles for myopia control
|
ACTIVE_COMPARATOR: Commercially available myopia control spectacles
|
Novel spectacles for myopia control
|
EXPERIMENTAL: Novel Myopia control spectacles - Prototype I
Experimental myopia control spectacles
|
Novel spectacles for myopia control
|
EXPERIMENTAL: Novel Myopia control spectacles - Prototype II
Experimental myopia control spectacles
|
Novel spectacles for myopia control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in axial length
Time Frame: one monthly interval for up to 6 months
|
Change in axial length measured using Lenstar
|
one monthly interval for up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vision and Choroidal Physiology
Time Frame: One monthly interval for up to 6 months
|
Vision and Choroidal Physiology determined using standard vision charts and Optical Coherence Tomography (OCT)
|
One monthly interval for up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Minh Huy Tran, M.D., Msc., Hai Yen Eye Care
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VCRTC2020-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopia
-
He Eye HospitalNot yet recruiting
-
University of BradfordCoopervision, Inc.; University of HuddersfieldNot yet recruiting
-
Visioneering Technologies, IncRecruitingMyopiaUnited States, Canada, Hong Kong, Singapore
-
University Eye Hospital, FreiburgRecruiting
-
Shanghai 10th People's HospitalCompletedMyopia | Myopia, ProgressiveChina
-
Tianjin Eye HospitalActive, not recruiting
-
Tianjin Eye HospitalCompleted
-
Sultan Qaboos UniversityChristian Medical College, Vellore, IndiaUnknown
-
Peking University People's HospitalUnknownProgressive MyopiaChina
-
Shanghai Eye Disease Prevention and Treatment CenterNot yet recruiting
Clinical Trials on Spectacles
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityUnknown
-
Johns Hopkins UniversityNational Health and Medical Research Council, AustraliaCompletedAstigmatism | Myopia | HyperopiaChina, India
-
Essilor InternationalQueensland University of TechnologyCompleted
-
Shanghai Eye Disease Prevention and Treatment CenterBrien Holden VisionRecruitingBlindness,Visual Impairment, Refractive Error, Cataract, High Myopia, AgingChina
-
Coopervision, Inc.CompletedAmetropiaUnited Kingdom
-
Avulux, Inc.Completed
-
London School of Hygiene and Tropical MedicineBritish Council for Prevention of Blindness; Tanzanian Society for the BlindCompletedUnder- and Uncorrected Significant Refractive ErrorsTanzania
-
Centre for Eye and Vision ResearchThe Hong Kong Polytechnic University; University of WaterlooRecruiting
-
Queen's University, BelfastUniversity of Ulster; University of Zimbabwe; L.V. Prasad Eye Institute; Clearly; New England College of Optometry and other collaboratorsCompletedHyperopia | Long SightZimbabwe
-
Jaeb Center for Health ResearchNational Eye Institute (NEI)Completed